AL-101

Oncotelic Therapeutics has successfully completed a Phase 1 trial evaluating OT-101, an antisense therapeutic targeting TGFβ2, in combination with IL-2 for advanced or metastatic solid tumors.

Alzamend Neuro partners with Tesla Dynamic Coils BV to develop a groundbreaking MRI head coil for measuring brain lithium levels across five Phase II clinical trials at Massachusetts General Hospital.

Alector anticipates topline data from the Phase 3 INFRONT-3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation (FTD-GRN) by Q4 2025.

Alector Therapeutics' AL002, an experimental antibody designed to activate microglia, failed to slow disease progression in a Phase 2 trial for early Alzheimer's disease.

The FDA has granted Breakthrough Therapy Designation to latozinemab for frontotemporal dementia with a progranulin gene mutation (FTD-GRN).